StockData

Sol-Gel Technologies vs Zentalis Pharmaceuticals

SLGL and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SLGL and ZNTL compare

Sol-Gel Technologies scores higher on the StockData Score (10 against 6 for Zentalis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSLGLZNTL
Size and price
Market cap–$107M
Share price$52.83$1.49
Change, 1 year55.4%12.0%
Change, 5 years−31.5%−98.0%
Beta (5Y)1.045.80
Employees28106
StockData Score
Total score10 (better)6
Valuation score01 (better)
Growth score2 (better)0
Performance score3 (better)0
Health score55
Dividend score00
Valuation
P/B–0.7×
FCF yield–−120%
Growth
Revenue growth (TTM)68.0%–
Revenue growth, 5Y average17.2%–
Profitability
Operating margin−38.9%–
Net margin−31.6%–
FCF margin1.4%–
Return on equity−15.3% (better)−66.7%
Return on invested capital−153%–
Financial health
Debt / equity0.000.00
Current ratio10.37 (better)4.82
Altman Z-score–−8.91
Piotroski F-score5 (better)1
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions47.5%66.1%
Held by insiders70.2%58.0%
Insider net buying, 12 months$11.0M$12.8M (better)
Short interest, % of float16.3%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.